Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.

Aastrom

Started by caliban , Sep 09 2009 06:58 PM

Please log in to reply

150 replies to this topic

#121 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 09 January 2012 - 01:23 PM

Stem Cell Therapy From Aastrom Biosciences and Cytori Therapeutics Looks to ...
Marketwire (press release) - Jan 9, 2012

NEW YORK, NY--(Marketwire - Jan 9, 2012) - Stem Cell stocks -- particularly companies focused on adult stems cells -- have performed well of late.

View the full article

#122 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 24 January 2012 - 01:23 PM

Breakthrough Therapy Using Cord Blood Banking Driving Stem Cell Industry
MarketWatch (press release) - 3 hours ago

NEW YORK, NY, Jan 24, 2012 (MARKETWIRE via COMTEX) -- Given some positive trends, the stem cell market could be set to skyrocket this year.

View the full article

#123 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 25 January 2012 - 07:28 AM

Will The Cord Blood America HYPE Continue?
eStocksDaily - 3 hours ago

There's a lot of talk lately about a little company by the name of Cord Blood America, Inc. (OTC:CBAI). Multiple press releases boasting a promising future, in a questionable sector seems to be keeping the attention of many traders as evidenced in ...

View the full article

#124 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 23 January 2012 - 04:26 PM

Aastrom's Renewed Momentum And Appreciation Before Anticipated Offering
Seeking Alpha - Jan 23, 2012

Aastrom Biosciences (ASTM) develops autologous cellular therapies for the treatment of severe and chronic cardiovascular diseases.

View the full article

#125 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 29 February 2012 - 09:39 PM

Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase ...
GlobeNewsWire (press release) - 3 hours ago

ANN ARBOR, Mich., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, has begun patient ...

View the full article

#126 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 01 March 2012 - 10:03 AM

Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase ...
Review seeker (press release) - 5 hours ago

By Globenewswire ANN ARBOR, Mich., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, ...

View the full article

#127 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 09 March 2012 - 04:02 PM

Aastrom Biosciences Completes $40 Million Financing
MarketWatch (press release) - 3 hours ago

ANN ARBOR, Mich., Mar 9, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced ...

Aastrom Shares Get Jolt from Cash Infusion (ASTM) - 24/7 Wall St.

View the full article

#128 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 09 March 2012 - 05:45 PM

Aastrom Raises Cash To Fund Pivotal Trial
TheStreet.com - 5 hours ago

By Adam Feuerstein 03/09/12 - 12:42 PM EST ANN ARBOR, Mich. (TheStreet) -- Aastrom BioSciences(ASTM) raised the cash it needs to pay for a phase III study of its personalized cellular therapy to treat severely blocked leg arteries.

View the full article

#129 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 09 March 2012 - 04:11 PM

Aastrom (ASTM) Closes Financing with Eastern Capital; Stock Issued at $3250/Share
StreetInsider.com (subscription) - 6 hours ago

Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that it has completed a $40 million private placement with Eastern Capital Limited in a financing structured and arranged by MLV & Co.

View the full article

#130 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 12 March 2012 - 08:47 PM

Aastrom Biosciences Q4 Loss Narrows
RTT News - 7 hours ago

(RTTNews) - Aastrom Biosciences Inc. (ASTM: News ), Monday reported fourth-quarter net loss of $2.8 million or $0.07 per share, compared to $13.2 million or $0.44 per share last year.

View the full article

#131 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 12 March 2012 - 01:03 PM

Aastrom to Present at 24th Annual ROTH Capital Conference
MarketWatch (press release) - 14 hours ago

ANN ARBOR, Mich., Mar 12, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, ...

View the full article

#132 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 19 March 2012 - 09:35 PM

Aastrom Biosciences (ASTM) Files 4.53M Common Shelf
StreetInsider.com (subscription) - 2 hours ago

Aastrom Biosciences (Nasdaq: ASTM) filed a registration with the US Securities and Exchange Commission to sell, from time to time, up to 4525978 shares of Common Stock.

View the full article

#133 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 14 March 2012 - 01:24 PM

Aastrom Biosciences Appoints Dr. LaVonne Lang as Head of Regulatory Affairs
MarketWatch (press release) - Mar 14, 2012

ANN ARBOR, Mich., Mar 14, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, ...

View the full article

#134 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 12 March 2012 - 08:13 PM

Aastrom Biosciences Reports Fourth Quarter and Year-End 2011 Financial Results
MarketWatch (press release) - Mar 12, 2012

ANN ARBOR, Mich., Mar 12, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported ...

Aastrom Biosciences Completes Private Placement of $40 Million â€“ NASDAQ:ASTM - Galaxy Stocks

View the full article

#135 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 10 March 2012 - 08:04 AM

Aastrom Biosciences fetches $40 million in stock sale to fund clinical trials
Crain's Detroit Business - Mar 10, 2012

By Tom Henderson Ann Arbor-based Aastrom Biosciences Inc. announced today that it has completed a private placement of $40 million of Series B convertible stock to fund the ongoing human clinical trials of one of its stem-cell-based therapies.

Aastrom Biosciences Completes $40 Million Financing - MarketWatch (press release)

View the full article

#136 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 26 March 2012 - 01:15 PM

Aastrom Biosciences to Present New Findings on Atheroprotective Effects of ...
MarketWatch (press release) - Mar 26, 2012

ANN ARBOR, Mich., Mar 26, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, ...

View the full article

#137 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 28 March 2012 - 08:47 PM

Aastrom to Present at the Needham & Company 11th Annual Healthcare Conference
NASDAQ - Mar 28, 2012

ANN ARBOR, Mich., March 28, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that ...

View the full article

#138 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 05 April 2012 - 01:00 PM

Aastrom Biosciences, Inc. Announces Final Results From RESTORE-CLI Phase 2b Clinical Trial For Ixmyelocel-T
Reuters Key Development - 2 hours ago

View the full article

#139 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 09 April 2012 - 02:49 PM

Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences
MarketWatch (press release) - 3 hours ago

LOS ANGELES, CA, Apr 09, 2012 (MARKETWIRE via COMTEX) -- Last month, Aastrom Biosciences, Inc. (UTD:ASTM) announced that it had completed an impressive, $40 million private placement financing.

View the full article

#140 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 11 April 2012 - 10:38 PM

Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences
Healthcare Global (press release) - 3 hours ago

LOS ANGELES, CA--(Marketwire - April 9, 2012) - Last month, Aastrom Biosciences, Inc. ( NASDAQ : ASTM ) announced that it had completed an impressive, $40 million private placement financing.

View the full article

#141 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 16 April 2012 - 02:15 PM

Upgrades & Downgrades: Lowe's Looks to Head Higher
Minyanville.com - 20 minutes ago

By Justin Sharon Apr 16, 2012 10:15 am Hoards of angry kilted clansmen converged on New York for the Tartan Day parade this weekend, and their ire was not solely due to having to make do with shabby Sixth Avenue while the bankrupt Greeks, Italians, ...

View the full article

#142 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 09 April 2012 - 02:49 PM

Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences
MarketWatch (press release) - Apr 9, 2012

LOS ANGELES, CA, Apr 09, 2012 (MARKETWIRE via COMTEX) -- Last month, Aastrom Biosciences, Inc. (UTD:ASTM) announced that it had completed an impressive, $40 million private placement financing.

View the full article

#143 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 05 April 2012 - 05:48 PM

Aastrom Biosciences Reports Results From RESTORE-CLI Phase 2b Clinical Trial
RTT News - Apr 5, 2012

(RTTNews) - Aastrom Biosciences Inc. (ASTM: News ) announced that final results from the company's RESTORE-CLI Phase 2b clinical trial for ixmyelocel-T were published in the peer-reviewed journal Molecular Therapy.

View the full article

#144 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 05 April 2012 - 01:04 PM

Final Results from RESTORE-CLI Phase 2b Clinical Trial for Ixmyelocel-T in ...
GlobeNewsWire (press release) - Apr 5, 2012

ANN ARBOR, Mich., April 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that ...

View the full article

#145 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 19 April 2012 - 05:52 PM

Stem Cell Research: Which Companies Will Emerge As Frontrunners?
Seeking Alpha - 1 hour ago

Advances in modern medicine have been significant as scientists fight to prevent and cure the hosts of injuries and diseases plaguing mankind.

View the full article

#146 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 23 April 2012 - 02:51 PM

Aastrom Biosciences sees calls surge
optionMONSTER Research (registration) - 3 hours ago

Aastrom Biosciences has running higher recently, and this morning's option activity is apparently looking for more. The cell-therapy company has seen its stock rise about 40 percent in the last month, ASTM is up another 1.56 percent today to trade at ...

View the full article

#147 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 24 April 2012 - 12:48 AM

Aastrom Biosciences Spokesperson Comments on Monday's Option Activity
Benzinga - Apr 24, 2012

By Greg Chalmers Aastrom Biosciences (NASDAQ: ASTM) call volume was at 4905% of average on Monday. There was no specific news to account for the option activity.

Aastrom Biosciences sees calls surge - optionMONSTER Research (registration)

View the full article

#148 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 30 April 2012 - 08:02 PM

Aastrom to Hold Annual Meeting of Shareholders on May 3, 2012
MarketWatch (press release) - 1 hour ago

ANN ARBOR, Mich., Apr 30, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (UTD:ASTM) , the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced ...

View the full article

#149 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 07 May 2012 - 10:16 PM

Aastrom To Present Results Of Phase 2a Clinical Trial Of Ixmyelocel-T
NASDAQ - May 7, 2012

(RTTNews.com) - Aastrom Biosciences Inc. (ASTM) announced that results from the company's Phase 2a clinical trial of ixmyelocel-T in the treatment of dilated cardiomyopathy or DCM will be presented at the Society for Cardiovascular Angiography and ...

View the full article

#150 ImmInst

Admin, Director robot
2,350 posts
72 ₮

Posted 09 May 2012 - 09:24 PM

Aastrom Biosciences Announces First Patient Enrolled in REVIVE Phase 3 ...
NASDAQ - 13 hours ago

ANN ARBOR, Mich., May 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that the ...

View the full article